Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.
In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs.
Here, we will give a short insight into our published results: Original publications
| Eingeschlossene Patienten: 21.393 (Stand 1. August 2022) | |
|---|---|
| Amgevita® (Adalimumab) | 153 |
| Benepali® (Etanercept) | 940 |
| Cimzia® (Certolizumab) | 986 |
| Enbrel® (Etanercept) | 2868 |
| Erelzi® (Etanercept) | 406 |
| Flixabi® (Infliximab) | 9 |
| Hulio® (Adalimumab) | 136 |
| Humira® (Adalimumab) | 2903 |
| Hyrimoz® (Adalimumab) | 135 |
| Idacio® (Adalimumab) | 41 |
| Imraldi® (Adalimumab) | 150 |
| Inflectra™ (Infliximab) | 16 |
| Jyseleca® (Filgotinib) | 63 |
| Kevzara® (Sarilumab) | 178 |
| Kineret® (Anakinra) | 89 |
| MabThera® (Rituximab) | 1459 |
| Nepexto® (Etanercept) | 25 |
| Olumiant® (Baricitinib) | 496 |
| Orencia® (Abatacept) | 912 |
| Remicade® (Infliximab) | 762 |
| Remsima® (Infliximab) | 12 |
| Rinvoq® (Upadacitinib) | 241 |
| Rixathon® (Rituximab) | 18 |
| RoActemra® (Tocilizumab) | 1335 |
| Ruxience® (Rituximab) | 1 |
| Simponi® (Golimumab) | 453 |
| Xeljanz® (Tofacitinib) | 387 |
| Zessly® (Infliximab) | 2 |
| Kontrollen | 6217 |
